- ACTIVE STOCK TRADERS: Get full access to Jim Cramer's thoughts for less than $3/week - sometimes before he says them on TV! Start with a 14-Day Free Trial.
The main thrust of the order appears to be easing regulatory hurdles to drug approvals, which could lower the cost of bringing new treatments to market and thus lower prices.
Slowing sales and safety concerns have some investors less than enthused, but Amgen says it's drugs in development could deliver.
Newly released neurotransmitter research could open up a $8 - $10 billion market as early as next year.